Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Cerliponase alfa (Primary)
- Indications Neuronal ceroid lipofuscinosis; Retinal disorders
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2023 primary endpoint has been amended.
- 11 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2021 New trial record